Beam Therapeutics Inc. (NASDAQ:BEAM) revealed new safety and efficacy data from its BEACON Phase 1/2 trial of BEAM-101 in ...
Only one quarter of patients living with sickle cell disease are prescribed disease modifying therapies, particularly newer ...
J&J aims to expand Darzalex's use even further in the blood cancer, while Merck & Co. and Novo Nordisk presented at ASH ...
When you give to Light Up A Lawn, Light Up A Life, you are supporting programs like Nationwide Children's cutting-edge gene ...
Beam Therapeutics reported promising trial data from seven sickle cell patients treated with their gene-edited therapy, ...
This results in red blood cells being destroyed, which is known as hemolytic anemia ... People with beta thalassemia trait will have elevation in hemoglobin A2 and/or F (fetal). There is no simple ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced longer-term data for CASGEVY™ (exagamglogene autotemcel) from global clinical trial ...
Johnson & Johnson today announced new frontline data featuring TECVAYLI® (teclistamab-cqyv) from two investigational studies in patients with newly diagnosed multiple myeloma (NDMM) in induction and ...
A drug developed by Sanofi raised platelet counts and reduced bleeding episodes in patients with a rare autoimmune disorder ...
Though he doesn't remember it, Branden Baptiste had his first sickle cell crisis at age 2. Through elementary school, he was ...
Though he doesn't remember it, Branden Baptiste had his first sickle cell crisis at age 2. Through elementary school, he was ...
MiNA Therapeutics Limited, the pioneer in small activating RNA (RNAa) therapeutics, today presented new pre-clinical data for its lead RNA activation program for the treatment of sickle cell disease, ...